Dahua Jixian: Upgrades Hengsen Pharmaceuticals (03692.HK) target price to HK$40, rating "buy"

According to the Wise Financial APP, Dahua JiXian released a research report stating that Johnson Pharmaceuticals (03692.HK) under Fujie has two new indications approved, with the NSCLC indication approved for the UK market. In addition, Hengmeida is also going to be used for the treatment of candidiasis and has obtained a drug registration certificate from the National Medical Products Administration; the company's other products are progressing smoothly in research and development. The bank is confident that sales of Ameile will reach 6 billion yuan in 2026 and the goal of 8 billion yuan in sales in the coming years. The rating is maintained as "buy", with the target price raised to 40 Hong Kong dollars (originally 29 Hong Kong dollars).